FDA就拒绝提供记录向天津海斯克尔医药科技签发警告信并列入进口警报66-79
FDA警告信:天津海斯克尔医药科技有限公司
FDA向天津海斯克尔医药科技有限公司签发警告信,指其拒绝提供704(a)(4)记录要求,并于2026年8月25日将其所有拟进口至美国的药品和药品制剂列入进口警报66-79。
近日,FDA向天津海斯克尔医药科技有限公司(FDA文件中写作 Tianjin Healthcare Medical Technology Co., Ltd.,下称THM)签发警告信(MARCS-CMS 736415,参考号320-27-15)。
这封的不同之处在于企业的理由。2026年6月17日FDA发出记录要求,6月24日企业回复称,将“停止生产相关(b)(4)产品”供美国市场,并拒绝提供所要求的文件。FDA在6月25日再次发函,提醒企业:你司生产的原料药已经进入美国市场,且仍在有效期内,所以记录仍然要交。企业答复:不会提供。
FDA在信里回了一句:单纯停止商业销售,或表示打算停产,都不能追溯性地免除监管义务。随后于2026年8月25日将THM所有拟进口至美国的药品和药品制剂列入进口警报66-79,并指出若确已不再为美国市场生产,须按21 CFR 207.29(a)(3)在停止运营后30个日历日内正式更新注册和药品列名。
翻译如下:
To Jianyu Zhao:
致 Jianyu Zhao:
This warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.
本警告信告知你司:FDA在审查你司设施提交的记录时发现了一项重大违规,并给予你司说明和处理的机会。本信并非违规的完整清单。确保你司符合联邦法律(包括FDA法规)的全部要求,是你司的责任。未充分处理任何违规,可能导致FDA在不另行通知的情况下采取监管行动。
Your facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).
你司设施——天津海斯克尔医药科技有限公司(下称THM),FDA企业识别号(FEI)3015495180,地址为天津自贸试验区(空港经济区)环河南路88号2-2066——在美国FDA注册为原料药(API)生产商。
A review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.
对进口记录的审查显示,有多批拟进入美国、用于药房配制的原料药,申报THM为药品生产商。FDA依据《联邦食品、药品和化妆品法案》(FD&C法案)第704(a)(4)条(21 U.S.C. 374(a)(4)),向你司注册档案中提供的联系邮箱发出索取记录和其他信息的要求。你司拒绝提供这些依法要求的记录。
It is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.
拒绝允许查阅或复制第704(a)条要求的任何记录,属于FD&C法案第301(e)条(21 U.S.C. 331(e))下的禁止行为。由于你司未回应第704(a)(4)条的记录要求及相关沟通尝试,我方无法了解你司设施所列药品的质量保证水平。
Refusal to Provide Records
拒绝提供记录
On June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant (b)(4) products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.
2026年6月17日,FDA向你司注册档案中提供的联系邮箱发送了电子记录要求。你司于2026年6月24日回复称,将“停止生产相关(b)(4)产品”供美国市场,并拒绝提供所要求的文件。2026年6月25日,FDA再次发出要求,告知你司所生产的原料药已进入美国市场且仍在有效期内,因此所要求的记录仍属必需。你司回复称不会提供所要求的记录。
Simply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.
单纯停止商业销售,或表示打算停产,都不能追溯性地免除你司的监管义务。
FDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.
FDA已于2026年8月25日将你司所有拟进口至美国的药品和药品制剂列入进口警报66-79。
If you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.
如果你司不再打算为美国市场生产或销售药品,必须正式更新注册和药品列名,以反映经营活动的变化。依据21 CFR 207.29(a)(3),设施必须在停止运营后30个日历日内更新注册。
Conclusion
结论
The violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.
本信所列违规并非你司设施全部违规的完整清单。
Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).
在FDA能够确认符合现行药品生产质量管理规范(CGMP)及其他适用要求之前,我方可能暂缓批准任何将你司列为药品生产商的新申请或补充申请。此外,THM(地址:天津自贸试验区(空港经济区)环河南路88号2-2066)生产并进入美国的物品,如疑似掺假或标签不当,可依据FD&C法案第801(a)(3)条(21 U.S.C. 381(a)(3))被扣留或拒绝入境。
In response to this letter, you may submit a request to schedule an FDA inspection.
作为对本信的回复,你司可提交安排FDA检查的申请。
Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.
请在收到本信后十五(15)个工作日内将书面回复发送至 CDER-OC-OMQ-Communications@fda.hhs.gov。请在邮件主题行注明 FEI 3015495180 及 ATTN: Marva Taylor。
If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.
如果你司认为有信息可证明你司产品未违反FD&C法案和FDA法规,请一并提供供我方考虑。
FDA posts warning letters to www.FDA.gov.
FDA将警告信公布于 www.FDA.gov。
Sincerely, /S/ Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
此致。签名:/S/ Francis Godwin(弗朗西斯·戈德温),主任,生产质量办公室,合规办公室,药品评价与研究中心,美国FDA
cc: U.S. agent
抄送:美国代理人
来源:制药经理人 · mp.weixin.qq.com